Home Apoptosis Caspase inhibitor - Antiviral inhibitor Emricasan (IDN-6556) For research use only.

Emricasan (IDN-6556)

Synonyms: PF 03491390, PF-03491390

Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.

Emricasan (IDN-6556) Chemical Structure

Emricasan (IDN-6556) Chemical Structure

CAS No. 254750-02-2

Purity & Quality Control

Products often used together with Emricasan (IDN-6556)

Y-27632 2HCl

Emricasan and Y-27632 2HCl combination exhibits synergistic effects on the cell survival of human embryonic stem cells (hESCs).

Chen Y, et al. Nat Methods. 2021;18(5):528-541.

MG132

Emricasan and MG132 combination results in reduction of the centriolar SAS-6 intensity in HeLa cells.

Seo MY, et al. Cell Death Dis. 2018 May 1;9(5):571.

Birinapant

Emricasan and Birinapant combination induce TNF expression and necroptosis in acute myeloid leukemia (AML) cells, MLL-ENL/MLL-AF9/HoxA9 + Meis1.

Brumatti G, et al. Sci Transl Med. 2016;8(339):339ra69.

Chroman 1

Emricasan and Chroman 1, in addition to other components, promote clonal growth and expansion of genetically stable human pluripotent stem cells (hPSCs).

Darwish T, et al. Biology (Basel). 2023 Aug 11;12(8):1119.

Emricasan (IDN-6556) Related Products

Signaling Pathway

Caspase Signaling Pathways

Caspase Signaling Pathway

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jurkat E6-1 Function assay Inhibition of Anti-Fas antibody-induced caspase-3 activity in human Jurkat E6-1 cells using Ac-DEVD-AMC substrate by fluorescence based assay, IC50 = 0.006 μM. 29650287
JFas Function assay Inhibitory concentration against JFas cells, IC50 = 0.025 μM. 16250635
THP-1 Function assay Inhibitory concentration against THP-1 cells, IC50 = 0.27 μM. 16250635
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
Targets
caspase [1]
In vitro
In vitro Emricasan, also called IDN-6556 or PF-03491390, is an inhibitor of activated caspases, and it has sub- to nanomolar activity in vitro. Emricasan shows neuroprotective activity for hNPCs but does not suppress ZIKV replication[2].
Cell Research Cell lines Astrocytes
Concentrations 9 μM
Incubation Time 1 h
Method Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.
Experimental Result Images Methods Biomarkers Images PMID
Growth inhibition assay Cell viability 27571349
In Vivo
In vivo Emricasan decreases liver injury but not metabolic derangement in NASH. It also ameliorates inflammation. In the murine NASH model, stellate cell activation and hepatic fibrogenesis are attenuated by administration of the pan-caspase inhibitor Emricasan[1]. Emricasan is currently being evaluated in phase 2 clinical trials for the reduction of hepatic injury and liver fibrosis caused by chronic HCV infection[2].
Animal Research Animal Models C57BL/6J mice
Dosages 0.3mg/kg/day
Administration i.g.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03205345 Unknown status
Decompensated Cirrhosis
Conatus Pharmaceuticals Inc.
 June 28 2017 Phase 2
NCT01653899 Completed
Diabetes
University of Alberta|Conatus Pharmaceuticals Inc.
 June 2012 Phase 1|Phase 2

Chemical Information & Solubility

Molecular Weight 569.50 Formula

C26H27F4N3O7
CAS No. 254750-02-2 SDF Download Emricasan (IDN-6556) SDF
Smiles CC(C(=O)NC(CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 100 mg/mL ( (175.59 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 25 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Emricasan (IDN-6556) | Emricasan (IDN-6556) supplier | purchase Emricasan (IDN-6556) | Emricasan (IDN-6556) cost | Emricasan (IDN-6556) manufacturer | order Emricasan (IDN-6556) | Emricasan (IDN-6556) distributor